Who Paid My Doc
Kevin Klos
Neurological Surgery Tulsa, OK Medical Doctor
NPI 1912923012 CMS profile 268058
7134 S Yale Ave, Ste 205, Tulsa, OK 74136
General payments
$20,697
Research payments
$73,466
Ownership & investment interest
$0
Research they led as principal investigator
$3,892,614
Through program year 2025, Kevin Klos of Tulsa, OK is reported in the CMS Open Payments database as having received $20,697 across 54 general payments and $73,466 in research payments paid to them. Separately, studies naming them as principal investigator received $3,892,614 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 90th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $18,586 | 18 | |
| 2025 | Research | $73,466 | 3 | |
| 2024 | General | $83 | 4 | |
| 2023 | General | $112 | 6 | |
| 2022 | General | $324 | 12 | |
| 2021 | General | $42 | 4 | |
| 2020 | General | $1,426 | 4 | |
| 2019 | General | $123 | 6 |
Beside peers
- Kevin Klos
- Neurological Surgery median
- Middle half of Neurological Surgery
- National median
In program year 2025, general payments to Kevin Klos were reported at $18,586. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.
Show as a table
| Year | Kevin Klos | Neurological Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $123 | $582 | $138–$3,006 | $163 |
| 2020 | $1,426 | $294 | $76–$2,174 | $114 |
| 2021 | $42 | $387 | $105–$2,432 | $132 |
| 2022 | $324 | $542 | $139–$2,989 | $149 |
| 2023 | $112 | $534 | $145–$2,697 | $160 |
| 2024 | $83 | $574 | $155–$3,046 | $164 |
| 2025 | $18,586 | $596 | $159–$3,102 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 36 drugsPart D claims
1,698
Drug cost
$375,297
Branded share of claims
69.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Rytary Carbidopa/Levodopa | Brand | 210 | $192,582 | |
| Neupro Rotigotine | Brand | 52 | $66,559 | |
| Xadago Safinamide Mesylate | Brand | 13 | $15,677 | |
| Carbidopa-Levodopa Carbidopa/Levodopa | Brand | 337 | $15,475 | |
| Carbidopa-Levodopa-Entacapone Carbidopa/Levodopa/Entacapone | Brand | 42 | $12,435 | |
| Crexont Carbidopa/Levodopa | Brand | 20 | $11,853 | |
| Amantadine Amantadine Hcl | Brand | 161 | $10,929 | |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | Brand | 137 | $9,994 | |
| Pramipexole Er Pramipexole Di-Hcl | Brand | 12 | $8,093 | |
| Quetiapine Fumarate Er Quetiapine Fumarate | Brand | 87 | $6,577 |
The 10 drugs with the highest cost, of 36 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 237 Part D prescribers listed as Neurological Surgery; they describe a distribution and say nothing about conduct.
Payments and prescribing
1 product · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| ONGENTYS |
|
$14 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
57 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Neurological Surgery in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Neurological Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.